Fused 1,2,4-thiadiazine derivatives, their preparation and use

Details Fused 1,2,4-thiadiazine derivatives, their preparation and use Fused 1,2,4-thiadiazine derivatives, their preparation and use

2000-03-30

2001-05-01

Shah, Mukund J. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S010000

Reexamination Certificate

active

06225310

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to fused 1,2,4-thiadiazine derivatives, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy e.g. in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
BACKGROUND OF THE INVENTION
Potassium channels play an important role in the physiological and pharmacological control of cellular membrane potential. Amongst the different types of potassium channels are the ATP-sensitive (K
ATP
-) channels which are regulated by changes in the intracellular concentration of adenosine triphosphate. The K
ATP
-channels have been found in cells from various tissues such as cardiac cells, pancreatic cells, skeletal muscles, smooth muscles, central neurons and adenohypophysis cells. The channels have been associated with diverse cellular functions for example hormone secretion (insulin from pancreatic beta-cells, growth hormone and prolactin from adenohypophysis cells), vasodilation (in smooth muscle cells), cardiac action potential duration, neurotransmitter release in the central nervous system.
Modulators of the K
ATP
-channels have been found to be of importance for the treatment of various diseases. Certain sulphonylureas which have been used for the treatment of non-insulin-dependent diabetes mellitus act by stimulating insulin release through an inhibition of the K
ATP
-channels on pancreatic beta-cells.
The potassium channel openers, which comprise a heterogeneous group of compounds, have been found to be able to relax vascular smooth muscles and have therefore been used for the treatment of hypertension. In addition, potassium channel openers can be used as bronchodilators in the treatment of asthma and various other diseases.
Furthermore, potassium channel openers have been shown to promote hairgrowth, and have been used for the treatment of baldness.
Potassium channel openers are also able to relax urinary bladder smooth muscle and therefore, can be used for the treatment of urinary incontinence. Potassium channel openers which relax smooth muscle of the uterus can be used for treatment of premature labor. By acting on potassium channels of the central nervous system these compounds can be used for treatment of various neurological and psychiatric diseases such as Alzheimer, epilepsia and cerebral ischemia.
Further, the compounds are found to be useful in the treatment of benign prostatic hyperplasia, erectile dysfunction and in contraception.
Compounds of the present invention, which inhibit insulin secretion by activating potassium channels of the beta-cell can be used in combination with other compounds which may be used to treat non-insulin dependent diabetes mellitus and insulin dependent diabetes mellitus. Examples of such compounds are insulin, insulin sensitizers, such as thiazolidinediones, insulin secretagogues, such as repaglinide, tolbutamide, glibenclamide and glucagon like peptide ( GLP1), inhibitors of &agr;-glucosidases and hepatic enzymes responsible for the biosynthesis of glucose.
Recently, it has been shown that Diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide) and certain 3-(alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide derivatives inhibit insulin release by an activation of K
ATP
-channels on pancreatic beta-cells (Pirotte B. et al.
Biochem. Pharmacol,
47, 1381-1386 (1994); Pirotte B. et al.,
J. Med. Chem.,
36, 3211-3213 (1993). Diazoxide has furthermore been shown to delay the onset of diabetes in BB-rats (Vlahos W D et al.
Metabolism
40, 39-46 (1991)). In obese zucker rats diazoxide has been shown to decrease insulin secretion and increase insulin receptor binding and consequently improve glucose tolerance and decrease weight gain (Alemzadeh R. et al. Endocrinol. 133, 705-712, 1993). It is expected that compounds which activate K
ATP
-channels can be used for treatment of diseases characterised by an overproduction of insulin and for the treatment and prevention of diabetes.
EP 618 209 discloses a class of pyridothiadiazine derivatives having an alkyl or an alkylamino group in position 3 of the thiadiazine ring. These compounds are claimed to be agonists at the AMPA-glutamate receptor.
In J. Med. Chem. 1980, 23, 575-577 the synthesis of 4(5)-amino-and formylaminoimidazo-5(4) carboxamide and their properties as agents of chemotherapeutic value are described. Especially, the compounds 3-aminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide and N-benzoylaminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide are shown.
DESCRIPTION OF THE INVENTION
The present invention relates to fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives of the general formula I:
wherein
B represents >NR
5
or >CR
5
R
6
, wherein R
5
and R
6
independently are hydrogen; hydroxy; C
1-6
-alkoxy; or C
1-6
-alkyl, C
3-6
,-cycloalkyl, C
2-6
-alkenyl or C
2-6
-alkynyl optionally mono- or polysubstituted with halogen; or R
5
and R
4
together represent one of the bonds in a double bond between the atoms 2 and 3 of formula I;
D represents —S(═O)
2
— or —S(═O)—; or
D—B represents —S(═O)(R
7
)═N—
wherein R
7
is C
1-6
-alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, C
1-6
-alkoxy, aryloxy, arylalkoxy, nitro, amino, C
1-6
-monoalkyl- or dialkylamino, cyano, acyl, or C
1-6
-alkoxycarbonyl;
R
1
is hydrogen; hydroxy; C
1-6
-alkoxy; or C
1-6
-alkyl, C
3-6
-cycloalkyl, C
2-6
-alkenyl or C
2-6
-alkynyl optionally mono- or polysubstituted with halogen and R
4
is hydrogen; or R
4
together with R
5
represent one of the bonds in a double bond between the atoms 2 and 3 of formula I; or R
1
together with R
4
represent one of the bonds in a double bond between the atoms 3 and 4 of formula I;
R
2
is hydrogen; hydroxy; C
1-6
-alkoxy; or C
1-6
-alkyl, C
3-6
-cycloalkyl, C
2-6
-alkenyl or C
2-6
-alkynyl optionally mono- or polysubstituted with halogen;
R
3
is R
8
; —OR
8
; —C(═X)R
8
; —NR
8
R
9
; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C
1-6
-alkoxy, aryloxy, arylalkoxy, nitro, amino, C
1-6
-monoalkyl- or dialkylamino, cyano, oxo, acyl or C
1-6
-alkoxycarbonyl; or aryl substituted with C
1-6
-alkyl;
wherein R
8
is hydrogen; C
3-6
-cycloalkyl or (C
3-6
-cycloalkyl)C
1-6
-alkyl, the C
3-6
-cycloalkyl group optionally being mono- or polysubstituted with C
1-6
-alkyl, halogen, hydroxy or C
1-6
-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or straight or branched C-
1-18
-alkyl optionally mono- or polysubstituted with halogen, hydroxy, C
1-6
-alkoxy, C
1-6
-alkylthio, C
3-6
-cycloalkyl, aryl, aryloxy, arylalkoxy, nitro, amino, C
1-6
-monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C
1-6
-alkoxy-carbonyl, or carbamoyl;
X is O or S;
R
9
is hydrogen; C
1-6
-alkyl; C
2-6
-alkenyl; C
3-6
-cycloalkyl optionally mono- or polysubstituted with C
1-6
-alkyl, halogen, hydroxy or C
1-6
-alkoxy; or
R
8
and R
9
together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C
1-6
-alkyl, hydroxy, C
1-6
-alkoxy, C
1-6
-alkoxy-C
1-6
-alkyl, nitro, amino, cyano, trifluoromethyl, C
1-6
-monoalkyl- or dialkylamino, oxo; or R
3
is
wherein n,m,p independently are 0,1,2,3 and R
10
is hydrogen; hydroxy; C
1-6
-alkoxy; C
3-6
-cycloalkyl optionally mono- or polysubstituted with C
1-6
-alkyl, halogen, hydroxy or C
1-6
-alkoxy; C
1-6
-alkyl, C
2-6
-alkenyl or C
2-6
-alkynyl optionally mono- or polysubstituted with halogen; or
R
2
and R
3
together with the nitrogen atom forms a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulf

Affiliated with

Also associated with

Rating

Fused 1,2,4-thiadiazine derivatives, their preparation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused 1,2,4-thiadiazine derivatives, their preparation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused 1,2,4-thiadiazine derivatives, their preparation and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2466285